title: ETS fusion genes in prostate cancer.
abstract: Prostate cancer is very common in elderly men in developed countries. Unravelling the molecular and biological processes that contribute to tumor development and progressive growth, including its heterogeneity, is a challenging task. The fusion of the genes ERG and TMPRSS2 is the most frequent genomic alteration in prostate cancer. ERG is an oncogene that encodes a member of the family of ETS transcription factors. At lower frequency, other members of this gene family are also rearranged and overexpressed in prostate cancer. TMPRSS2 is an androgen-regulated gene that is preferentially expressed in the prostate. Most of the less frequent ETS fusion partners are also androgen-regulated and prostate-specific. During the last few years, novel concepts of the process of gene fusion have emerged, and initial experimental results explaining the function of the ETS genes ERG and ETV1 in prostate cancer have been published. In this review, we focus on the most relevant ETS gene fusions and summarize the current knowledge of the role of ETS transcription factors in prostate cancer. Finally, we discuss the clinical relevance of TMRPSS2-ERG and other ETS gene fusions in prostate cancer.
authors.affiliation: Departments of Pathology Urology, Erasmus University Medical Centre, PO Box 2040, 2000 CA Rotterdam, The Netherlands.
authors.forename: Delila
authors.initials: D
authors.lastname: Gasi Tandefelt
authors.forename: Joost
authors.initials: J
authors.lastname: Boormans
authors.forename: Karin
authors.initials: K
authors.lastname: Hermans
authors.forename: Jan
authors.initials: J
authors.lastname: Trapman
mesh_terms: D000818:Animals; D006801:Humans; D008297:Male; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000235:genetics*; D050783:Proto-Oncogene Proteins c-ets / Q000235:genetics*
chemical_list: D015514:Oncogene Proteins, Fusion; D050783:Proto-Oncogene Proteins c-ets
keywords: ETS gene; androgen regulation; gene fusion; prostate cancer; prostate specific; translocation